AXL in cancer: a modulator of drug resistance and therapeutic target

被引：34
作者：
Tang, Yaoxiang [1 ]
Zang, Hongjing [1 ]
Wen, Qiuyuan [1 ]
Fan, Songqing [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2023年 / 42卷 / 01期
基金：
中国国家自然科学基金;
关键词：
AXL; Cancer; Drug resistance; Target therapy; Molecular mechanisms; RECEPTOR TYROSINE KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; BREAST-CANCER; DNA-DAMAGE; GAS6/AXL AXIS; EGFR-TKI; INHIBITION; PROMOTES;
D O I：
10.1186/s13046-023-02726-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. There is mounting evidence supporting AXL's role in the occurrence and progression of cancer, as well as drug resistance and treatment tolerance. Recent studies revealed that reducing AXL expression can weaken cancer cells' drug resistance, indicating that AXL may be a promising target for anti-cancer drug treatment. This review aims to summarize the AXL's structure, the mechanisms regulating and activating it, and its expression pattern, especially in drug-resistant cancers. Additionally, we will discuss the diverse functions of AXL in mediating cancer drug resistance and the potential of AXL inhibitors in cancer treatment.
引用
收藏
页数：14
相关论文
共 113 条
  • [11] Tissue Microarray Analyses Suggest Axl as a Predictive Biomarker in HPV-Negative Head and Neck Cancer
    Busch, Chia-Jung
    Hagel, Christian
    Becker, Benjamin
    Oetting, Agnes
    Moeckelmann, Nikolaus
    Droste, Conrad
    Moeller-Koop, Christina
    Witt, Melanie
    Blaurock, Markus
    Loges, Sonja
    Rothkamm, Kai
    Betz, Christian
    Muenscher, Adrian
    Clauditz, Till S.
    Rieckmann, Thorsten
    [J]. CANCERS, 2022, 14 (07)
  • [12] Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
    Cabanos, Heidie Frisco
    Hata, Aaron N.
    [J]. CANCERS, 2021, 13 (11)
  • [13] AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
    Cardone, Claudia
    Blauensteiner, Bernadette
    Moreno-Viedma, Veronica
    Martini, Giulia
    Simeon, Vittorio
    Vitiello, Pietro P.
    Ciardiello, Davide
    Belli, Valentina
    Matrone, Nunzia
    Troiani, Teresa
    Morgillo, Floriana
    Marino, Federica Zito
    Dentice, Monica
    Nappi, Annarita
    Boccaccino, Alessandra
    Antoniotti, Carlotta
    Cremolini, Chiara
    Pietrantonio, Filippo
    Prager, Gerald W.
    Normanno, Nicola
    Maiello, Evaristo
    Argiles, Guillem
    Elez, Elena
    Signoriello, Giuseppe
    Franco, Renato
    Falcone, Alfredo
    Tabernero, Josep
    Sibilia, Maria
    Ciardiello, Fortunato
    Martinelli, Erika
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : 1 - 10
  • [14] Targeting Axl With an High-affinity Inhibitory Aptamer
    Cerchia, Laura
    Esposito, Carla L.
    Camorani, Simona
    Rienzo, Anna
    Stasio, Loredana
    Insabato, Luigi
    Affuso, Andrea
    de Franciscis, Vittorio
    [J]. MOLECULAR THERAPY, 2012, 20 (12) : 2291 - 2303
  • [15] Polytherapy and Targeted Cancer Drug Resistance
    Chatterjee, Nilanjana
    Bivona, Trever G.
    [J]. TRENDS IN CANCER, 2019, 5 (03): : 170 - 182
  • [16] Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) sensitize melanoma cells to MEK inhibition and inhibit metastasis and relapse by inducing degradation of AXL
    Chen, Yingshi
    Zhang, Yiwen
    Chen, Siqi
    Liu, Weiwei
    Lin, Yingtong
    Zhang, Hui
    Yu, Fei
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2022, 35 (02) : 238 - 251
  • [17] Engineering Axl specific CAR and SynNotch receptor for cancer therapy
    Cho, Jang Hwan
    Okuma, Atsushi
    Al-Rubaye, Dalal
    Intisar, Ejaj
    Junghans, Richard P.
    Wong, Wilson W.
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [18] Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance
    D'Errico, Gabriele
    Alonso-Nocelo, Marta
    Vallespinos, Mireia
    Hermann, Patrick C.
    Alcala, Sonia
    Pedrero Garcia, Coral
    Martin-Hijano, Laura
    Valle, Sandra
    Earl, Julie
    Cassiano, Chiara
    Lombardia, Luis
    Feliu, Jaime
    Monti, Maria Chiara
    Seufferlein, Thomas
    Garcia-Bermejo, Laura
    Martinelli, Paola
    Carrato, Alfredo
    Sainz, Bruno, Jr.
    [J]. ONCOGENE, 2019, 38 (27) : 5469 - 5485
  • [19] Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma
    de Miguel-Perez, Diego
    Isabel Bayarri-Lara, Clara
    Gabriel Ortega, Francisco
    Russo, Alessandro
    Moyano Rodriguez, Maria Jose
    Jesus Alvarez-Cubero, Maria
    Maza Serrano, Elizabeth
    Antonio Lorente, Jose
    Rolfo, Christian
    Jose Serrano, Maria
    [J]. CANCERS, 2019, 11 (11)
  • [20] Therapeutic aspects of the Axl/Gas6 molecular system
    Di Stasi, Rossella
    De Rosa, Lucia
    D'Andrea, Luca D.
    [J]. DRUG DISCOVERY TODAY, 2020, 25 (12) : 2130 - 2148
12345678910